Market Rundown: US Banks, Pharma Price Cuts, and Micron's China Strategy

Banking Sector Fears Reignited

• 🏦 Regional banks are causing renewed panic on Wall Street, with financial stocks plunging on Thursday.
• 📉 Zion's Bank Core posted a $50 million loss tied to troubled California loans, and Western Alliance saw an 11% drop due to similar exposure.
• 💸 The market reaction saw 74 of the biggest US banks shed over a hundred billion dollars in market value, raising questions about the era of freewheeling capital.

Yen Rebounds Amidst Political Uncertainty

• 📈 Japan's currency, the yen, rose above 150 versus the US dollar, recovering from an eight-month low.
• 🗳️ This rebound is occurring despite uncertainty surrounding the formation of a coalition government after Japan's prime minister vote.
• 🏦 The Bank of Japan might tighten policy if confidence in the recovery improves, according to Governor UEA.

Geopolitical Developments and Peace Talks

• 🕊️ President Trump has revived efforts to end the Ukraine war, scheduling a second meeting with Russian President Putin.
• 🇺🇦 This initiative precedes a meeting with Ukrainian President Zelensky, who is expected to request air defenses and Tomahawk missiles.
• ⚠️ Both Putin and Trump have indicated that sending advanced missiles to Ukraine could derail peace negotiations.

Big Pharma Price Cut Speculation

• 💊 President Trump has targeted big pharma, suggesting that the price of drugs like Ozempic could be reduced to as low as $150 a month.
• 📉 Eli Lilly and Novo Nordisk experienced drops in late trading following these remarks.
• 🤝 While Trump indicated prices would fall quickly, the CDC chief stated that negotiations are still ongoing.

Micron's Strategic Shift in China

• 💻 Micron plans to stop supplying server chips to Chinese data centers, according to Reuters sources.
• 🇨🇳 This move comes after a 2023 ban restricted Micron's products from critical infrastructure in China.
• 🏭 Micron was the first US chipmaker targeted by Beijing, with Intel and Nvidia also facing scrutiny.